{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T23:20:46Z","timestamp":1794525646525,"version":"4.9.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:00:00Z","timestamp":1755216000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:00:00Z","timestamp":1755216000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"DOI":"10.1186\/s10194-025-02126-9","type":"journal-article","created":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T09:31:43Z","timestamp":1755250303000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Longitudinal assessment of migraine burden in resistant and refractory migraine \u2013 Data from the prospective REFINE study"],"prefix":"10.1186","volume":"26","author":[{"given":"Umberto","family":"Pensato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Ornello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Rosignoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Caponnetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnese","family":"Onofri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Braschinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Sved","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Gil-Gouveia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Lampl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"Paungarttner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Martelletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William David","family":"Wells-Gatnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel Pavao","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimos D.","family":"Mitsikostas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loukia","family":"Apostolakopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aynur","family":"Ozge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilan Bayar","family":"Narin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Pozo-Rosich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Munoz-Vendrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Pia","family":"Prudenzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martino","family":"Gentile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Ryliskiene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurgita","family":"Vainauskiene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"Sanchez-del-Rio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Vernieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianmarco","family":"Iaccarino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Waliszewska-Pros\u00f3\u0142","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u0142awomir","family":"Budrewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Carnovali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaza","family":"Katsarava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Sacco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,15]]},"reference":[{"key":"2126_CR1","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1016\/S0140-6736(24)00757-8","volume":"403","author":"Global incidence","year":"2024","unstructured":"Global incidence (2024) prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990\u20132021: a systematic analysis for the global burden of disease study 2021. Lancet 403:2133\u20132161","journal-title":"Lancet"},{"key":"2126_CR2","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/S1474-4422(24)00038-3","volume":"23","author":"Global","year":"2024","unstructured":"Global (2024) regional, and National burden of disorders affecting the nervous system, 1990\u20132021: a systematic analysis for the global burden of disease study 2021. Lancet Neurol 23:344\u2013381","journal-title":"Lancet Neurol"},{"key":"2126_CR3","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/s41572-021-00328-4","volume":"8","author":"MD Ferrari","year":"2022","unstructured":"Ferrari MD, Goadsby PJ, Burstein R et al (2022) Migraine Nat Rev Dis Primers 8:2","journal-title":"Migraine Nat Rev Dis Primers"},{"key":"2126_CR4","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41582-018-0003-1","volume":"14","author":"L Edvinsson","year":"2018","unstructured":"Edvinsson L, Haanes KA, Warfvinge K, Krause DN (2018) CGRP as the target of new migraine therapies - successful translation from bench to clinic. Nat Rev Neurol 14:338\u2013350","journal-title":"Nat Rev Neurol"},{"key":"2126_CR5","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s10194-023-01567-4","volume":"24","author":"L Al-Hassany","year":"2023","unstructured":"Al-Hassany L, Boucherie DM, Creeney H et al (2023) Future targets for migraine treatment beyond CGRP. J Headache Pain 24:76","journal-title":"J Headache Pain"},{"key":"2126_CR6","doi-asserted-by":"publisher","first-page":"104943","DOI":"10.1016\/j.ebiom.2023.104943","volume":"99","author":"R Ornello","year":"2024","unstructured":"Ornello R, Andreou AP, De Matteis E, J\u00fcrgens TP, Minen MT, Sacco S (2024) Resistant and refractory migraine: clinical presentation, pathophysiology, and management. EBioMedicine 99:104943","journal-title":"EBioMedicine"},{"key":"2126_CR7","doi-asserted-by":"publisher","first-page":"898219","DOI":"10.3389\/fneur.2022.898219","volume":"13","author":"JD Santoro","year":"2022","unstructured":"Santoro JD, Moon PK, Han M et al (2022) Early onset diffusion abnormalities in refractory headache disorders. Front Neurol 13:898219","journal-title":"Front Neurol"},{"issue":"Suppl 4","key":"2126_CR8","first-page":"S182","volume":"46","author":"D Dodick","year":"2006","unstructured":"Dodick D, Silberstein S (2006) Central sensitization theory of migraine: clinical implications. Headache 46(Suppl 4):S182\u2013S191","journal-title":"Headache"},{"key":"2126_CR9","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s10194-019-1040-x","volume":"20","author":"L D\u2019Antona","year":"2019","unstructured":"D\u2019Antona L, Matharu M (2019) Identifying and managing refractory migraine: barriers and opportunities? J Headache Pain 20:89","journal-title":"J Headache Pain"},{"key":"2126_CR10","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1111\/j.1526-4610.2008.01135.x","volume":"48","author":"EA Schulman","year":"2008","unstructured":"Schulman EA, Brahin EJ (2008) Refractory headache: historical perspective, need, and purposes for an operational definition. Headache 48:770\u2013777","journal-title":"Headache"},{"key":"2126_CR11","doi-asserted-by":"publisher","first-page":"333102423120930","DOI":"10.1177\/03331024231209303","volume":"43","author":"U Pensato","year":"2023","unstructured":"Pensato U, Cevoli S, Pierangeli G, Cortelli P (2023) The evolutionary meaning of migraine. Cephalalgia 43:3331024231209303","journal-title":"Cephalalgia"},{"key":"2126_CR12","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/1129-2377-15-47","volume":"15","author":"P Martelletti","year":"2014","unstructured":"Martelletti P, Katsarava Z, Lampl C et al (2014) Refractory chronic migraine: a consensus statement on clinical definition from the European headache federation. J Headache Pain 15:47","journal-title":"J Headache Pain"},{"key":"2126_CR13","doi-asserted-by":"crossref","unstructured":"Schulman EA, Lake AE 3rd, Goadsby PJ et al (2008) Defining refractory migraine and refractory chronic migraine: proposed criteria from the Refractory Headache Special Interest Section of the American Headache Society. Headache.;48:778\u2013\u200982","DOI":"10.1111\/j.1526-4610.2008.01132.x"},{"key":"2126_CR14","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1111\/j.1468-2982.2006.01173.x","volume":"26","author":"PJ Goadsby","year":"2006","unstructured":"Goadsby PJ, Schoenen J, Ferrari MD, Silberstein SD, Dodick D (2006) Towards a definition of intractable headache for use in clinical practice and trials. Cephalalgia 26:1168\u20131170","journal-title":"Cephalalgia"},{"key":"2126_CR15","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s10194-020-01130-5","volume":"21","author":"S Sacco","year":"2020","unstructured":"Sacco S, Braschinsky M, Ducros A et al (2020) European headache federation consensus on the definition of resistant and refractory migraine: developed with the endorsement of the European migraine & headache alliance (EMHA). J Headache Pain 21:76","journal-title":"J Headache Pain"},{"key":"2126_CR16","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s10194-024-01910-3","volume":"25","author":"C Rosignoli","year":"2024","unstructured":"Rosignoli C, Ornello R, Caponnetto V et al (2024) Resistant and refractory migraine - two different entities with different comorbidities? Results from the REFINE study. J Headache Pain 25:212","journal-title":"J Headache Pain"},{"key":"2126_CR17","doi-asserted-by":"crossref","unstructured":"Headache Classification Committee of the International Headache Society (IHS) (2018);38:1-211","DOI":"10.1177\/0333102417738202"},{"key":"2126_CR18","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1007\/s42399-021-00868-6","volume":"3","author":"AG Voloshin","year":"2021","unstructured":"Voloshin AG, Moiseeva IV (2021) Combined interventional treatment of refractory chronic migraine. SN Compr Clin Med 3:1320\u20131326","journal-title":"SN Compr Clin Med"},{"key":"2126_CR19","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s10194-018-0913-8","volume":"19","author":"TP Do","year":"2018","unstructured":"Do TP, Heldarskard GF, Kolding LT, Hvedstrup J, Schytz HW (2018) Myofascial trigger points in migraine and tension-type headache. J Headache Pain 19:84","journal-title":"J Headache Pain"},{"key":"2126_CR20","doi-asserted-by":"publisher","first-page":"333102423115767","DOI":"10.1177\/03331024231157677","volume":"43","author":"V Favoni","year":"2023","unstructured":"Favoni V, Mascarella D, Giannini G et al (2023) Prevalence, natural history and dynamic nature of chronic headache and medication overuse headache in italy: the SPARTACUS study. Cephalalgia 43:3331024231157677","journal-title":"Cephalalgia"},{"key":"2126_CR21","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s10194-017-0787-1","volume":"18","author":"D Serrano","year":"2017","unstructured":"Serrano D, Lipton RB, Scher AI et al (2017) Fluctuations in episodic and chronic migraine status over the course of 1 year: implications for diagnosis, treatment and clinical trial design. J Headache Pain 18:101","journal-title":"J Headache Pain"},{"key":"2126_CR22","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s11916-023-01152-z","volume":"27","author":"CS White","year":"2023","unstructured":"White CS (2023) Unique considerations in episodic migraine: underserved populations. Curr Pain Headache Rep 27:503\u2013509","journal-title":"Curr Pain Headache Rep"},{"key":"2126_CR23","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1111\/head.14154","volume":"61","author":"R Ishii","year":"2021","unstructured":"Ishii R, Schwedt TJ, Dumkrieger G et al (2021) Chronic versus episodic migraine: the 15-day threshold does not adequately reflect substantial differences in disability across the full spectrum of headache frequency. Headache 61:992\u20131003","journal-title":"Headache"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-025-02126-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-025-02126-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-025-02126-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T02:35:35Z","timestamp":1757385335000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-025-02126-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,15]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2126"],"URL":"https:\/\/doi.org\/10.1186\/s10194-025-02126-9","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,15]]},"assertion":[{"value":"14 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Participants or their authorized representatives provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"PM serves as the Editor-in-Chief of The Journal of Headache and Pain and SN Comprehensive Clinical Medicine. M.W-P is a member of the Editorial Board of The Journal of Headache and Pain. RO reports personal fees or non-financial support from AbbVie, Bayer, Eli Lilly, Lundbeck, Novartis, Organon, Pfizer, and Teva; he is an Editorial Board Member of The Journal of Headache and Pain, Confinia Cephalalgica, and Associate Editor for Frontiers in Neurology and Arquivos de Neuropsiquiatria. PP-R reports in the last 36 months, fees as a consultant and speaker for: AbbVie, Dr. Reddy\u2019s, Eli Lilly, Lundbeck, Medscape, Novartis, Organon, Pfizer and Teva. Her research group has received research grants from AbbVie, Novartis and Teva; as well as, InstitutoSalud Carlos III, EraNet Neuron, European Regional Development Fund (001-P-001682) under theframework of the FEDER Operative Programme for Catalunya 2014-2020 - RIS3CAT; has receivedfunding for clinical trials from AbbVie, Amgen, Biohaven, Eli Lilly, Lundbeck, Novartis, Pfizer Teva. SS reports personal fees as speaker or advisor from Abbott, Allergan-Abbvie, AstraZeneca, Bayer, Boehringer, Eli Lilly, Lundbeck, Pfizer, and Teva; she received research grants from Novartis and Uriach; she is President of the European Stroke Organisation, Editor-in-Chief of Cephalalgia and Cephalalgia Reports, and Assistant Editor for Stroke. DM has received fees and travel grants from AbbVie, Bristol Myers Squibb, Cross Pharma, Eli Lilly, Genesis Pharma, Haleon, Merck, Lundbeck, Novartis, Orion, Roche, Pfizer, Viatris, AstraZeneca, and Teva Pharmaceuticals; has participated in clinical trials for Amgen, Eli Lily, Lundberg, Novartis, Pfizer, and Teva Pharmaceuticals, as principal investigator; is president of the Hellenic Headache Society; is a member of the Management Group of the Headache Scientific Panel and of the Coordinating panel for the Functional Neurological Disorders at the European Academy of Neurology; and a past-President of the European Headache Federation. AO reports receiving personal fees as a speaker or advisor from AbbVie, Eli Lilly, TEVA, Pfizer, Organon, Ali Raif, \u0130lko, and Neutec. She is a board member of IHS. She is the current president of the Global Migraine and Pain Society and MENAA Headache Society. She serves as a guest editor or reviewer for several Journals, including Cephalalgia, Cephalalgia Reports, TJHP, BMC Neurology, Headache, and Frontiers in Neurology. FV received travel grants, honoraria for advisory board, speaker panels, or clinical investigation studies from Allergan\/AbbVie, Angelini, Eli Lilly, Lundbeck, Novartis, Pfizer, and Teva Pharmaceuticals; he serves as Specialty Chief Editor of Frontiers in Neurology Headache and Neurogenic Pain section. MB previously received sponsorship, financial support, fees from: Abbott Laboratories, AbbVie Inc, Allergan Inc, Berlin-Chemie AG (Menarini Group), Boehringer Ingelheim Pharma GmbH, Desitin Arzneimittel GmbH, EV3, Gedeon Richter Ltd, GlaxoSmithKline, KBM Pharma Ltd., H. Lundbeck A\/S, Novartis Pharma Services Inc, Nycomed SEFA, Orion Pharma, Pfizer Inc, Sanofi-Aventis, Sandoz d.d., Scanmed Group, Solvay Pharmaceuticals, Teva Pharmaceutical Industries Ltd.\/Sicor Biotech UAB, Zentiva International.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"was obtained from the Institutional Review Board and\/or relevant Ethics Committees at all participating centers (protocol number from coordinating center: 45\/2020-21). Participants or their authorized representatives provided written informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}}],"article-number":"184"}}